STAAR Surgical is trading 6.93% up at $24.00, with no clearly identified company-specific catalyst for September 16, 2026.
- Investor attention has centered on strong quarterly sales, a return to profitability, China-led growth, and executive appointments, but these developments predate the move and do not establish direct causation.
- Broader futures are modestly higher ahead of retail-sales data and the Federal Reserve decision, though the market backdrop is not strong enough to explain the gain confidently.